EXEL

Exelixis, Inc.

20.84 USD
+0.12 (+0.58%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Exelixis, Inc. stock is down -5.74% since 30 days ago. The next earnings date is May 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 23 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 67% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Jan 17:30 17 May, 2024 20.00 PUT 5591 675
22 Jan 18:32 17 Jan, 2025 20.00 CALL 50 613
25 Jan 15:19 17 May, 2024 22.00 PUT 282 111
12 Feb 16:29 16 Aug, 2024 26.00 PUT 66 1
13 Feb 16:04 17 May, 2024 21.00 PUT 788 1639
15 Feb 17:50 17 May, 2024 21.00 PUT 1142 1340
15 Feb 17:52 17 May, 2024 20.00 PUT 6987 7580
15 Feb 19:20 17 May, 2024 20.00 PUT 3781 7580
16 Feb 20:48 17 Jan, 2025 17.00 CALL 50 187
21 Feb 14:35 16 Jan, 2026 20.00 PUT 126 3

About Exelixis, Inc.

Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Its products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma.

  • RBC Capital
    Wed Feb 7, 12:19
    buy
    confirm
  • Stifel
    Fri Feb 2, 14:27
    hold
    confirm
  • Barclays
    Tue Jan 30, 05:36
    buy
    confirm